AntriaBio

Investors

Press Releases

Jul 24, 2019 Rezolute Completes $45 Million Investment Round with Full Exercise of $20 Million Option
Jan 7, 2019 Rezolute Announces $25 Million Private Placement -- Potential Total Investment of $45 Million
May 16, 2018 Rezolute Announces Appointment of Keith Vendola as Chief Financial Officer
Apr 9, 2018 Rezolute Announces Appointment of Congenital Hyperinsulinism Therapeutic Area Expert, Dr. Christine Ferrara, as Director of Clinical Development
Apr 4, 2018 Rezolute Announces Appointment of Hoyoung Huh, M.D., Ph.D. as Vice Chairman of its Board of Directors
Apr 3, 2018 Rezolute, Inc. Announces Close of Convertible Note Financing
Dec 26, 2017 UPDATE - Rezolute, Inc. Enters into Common Stock Purchase Agreement for Up to $10 Million with Lincoln Park Capital Fund, LLC
Dec 7, 2017 AntriaBio Announces Exclusive License Agreement for a Phase 2 Orphan Disease Therapy with XOMA Corporation and Name Change to Rezolute, Inc.
Oct 17, 2017 AntriaBio Announces Selection of Lead Oral Plasma Kallikrein Inhibitor Candidates for the Treatment of Diabetic Retinopathy, Diabetic Macular Edema and Hereditary Angioedema
Oct 9, 2017 AntriaBio Appoints Nektar Therapeutics CFO to its Board of Directors

<< Previous
1
2
3
4
5
6
7
8
9
Next >>

Show All